Senior Scientist
The Ottawa Hospital Research Institute, Canada
Dr. Jean-Simon Diallo obtained his Master’s degree in Biochemistry at McGill University in 2003 and his Ph.D in molecular biology at the Université de Montréal in 2008. During his postdoctoral fellowship with oncolytic virotherapy pioneer Dr. John Bell, Dr. Diallo worked on using oncolytic viruses to treat cancer and discovered a host of “viral sensitizer” molecules that enhance viral infection. He is now a Senior Scientist at the Ottawa Hospital Research Institute and Associate Professor at the University of Ottawa in the department of Biochemistry Microbiology and immunology. With nearly 70 peer-reviewed manuscripts and 10 licensed patents, Dr. Diallo has a decade experience in oncolytic virus translational development and has established himself as a key opinion leader in the oncolytic virus field. Since 2018, Dr. Diallo is also Founder and Chief Executive Officer at Virica Biotech Inc., which is commercializing viral sensitizer technology for for virus and cell and gene therapy manufacturing.
